Navigation Links
Biodesix Supports Unique Lung Cancer Research Initiative
Date:4/28/2011

BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy"). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate and accelerate the development and delivery of diagnostic tests and treatments tailored to the individual patient. As part of the study, Biodesix is performing VeriStrat® testing on eligible patients and serving as ALCMI's biorepository for all serum samples collected from CASTLE study subjects for future research. VeriStrat is a serum proteomic test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib.

Biodesix is committed to advancing the field of personalized medicine by developing unique and clinically useful diagnostic tests in oncology. This collaboration is the first of its kind in bringing together leading lung cancer scientists in the U.S. and Europe, patient advocates, and diagnostic laboratories to collect biospecimens with the intent of developing personalized therapies and tests that could improve patient outcomes. "We are pleased to offer the only serum-based testing for the CASTLE study and play an integral role in this collaboration" commented Paul Beresford, Biodesix' Vice President in charge of the company's laboratory operations. "We look forward to supporting our ALCMI colleagues in their efforts to accelerate translational medicine in lung cancer and continuing to shift the standard of care toward widespread use of molecular testing in clinical decision-making."

About NSCLC: As reported by the American Cancer Society, lung cancer is the leadi
'/>"/>

SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. The SCOOTER Store Supports Fight Against Multiple Sclerosis
2. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
3. Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare Competitive Bidding Program for Homecare
4. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
5. Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event
6. Leader Ventures Supports Innovative Drug Discovery Company Carmot
7. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
8. Philips Announces Its Portfolio of Lifesaving Solutions Supports New American Heart Association 2010 CPR and ECC Guidelines
9. Netsmart Technologies Software Supports Shawnee Mental Health Center Integrated Mental Health and Primary Care Initiative
10. Alliance Seating & Mobility Supports Community Efforts to Help Paralyzed North Carolina Resident
11. New Mask Study Supports CDCs Updated Guidance for Seasonal Flu Prevention Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Deutsche Bank 38 th ... 2013 at 8:40 a.m. ET in Boston, MA. ... presentation will be available on the "Investors & Media" section ... will be available on the Isis Web site within 48 ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Compound, AHLi-11, Slated for IND Filing By ... ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering and,developing novel ... the State University of New York at,Buffalo, Center for Hearing & ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... dedicated to protecting the rights of victims injured by ... that Senior Litigation Counsel Matthew J. McCauley has been ... entitled In Re: Mirena IUD Products Liability Litigation (Case ... states that Co-Lead and Liaison Counsel are to submit ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Teen birth rates in the ... to a new government report. Overall, the rate of ... one half from 1991 to 2011 -- from about 62 ... 1,000. From 2007 to 2011, the most recent time ... 31. During that time, rates fell at least 30 ...
(Date:5/23/2013)... (HealthDay News) -- A shortage of a critical tuberculosis ... the United States to contain the spread of the ... drug, isoniazid (INH), was first used in 1951 and ... core of any first-line treatment for tuberculosis (TB). Patients ... according to the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... good job of aggressively treating the early stages of ... diagnosis. The study involved 467 hospitals spread across 12 ... that patients may be treated less aggressively when they ... able to confirm the diagnosis,” said Chadwick Miller, M.D., ...
... Heart failure patients with untreated sleep apnea are more likely to ... ,The study followed 164 patients with heart failure for ... apnea (OSA) had double the death rate of those patients who ... OSA, the death rate was 24% in contrast to 12% for ...
... in the fight against obesity has started delivering results in ... pilot program was started in one of the middle schools ... eating habits among school children. ,Today nearly ... this three year old program called ‘Healthy School.’ ...
... that smoking and binge drinking among teenage girls have ... the health risks seem less important than those of ... young people correctly see cigarettes and alcohol as a ... to reflect that, Ofsted opined. Pupils also felt let ...
... NHS services’, UK ‘s Health Minister Patricia Hewitt launched ... select their hospital and doctor, as well as access information on ... to put patients at the heart of the NHS and making ... a crucial part of that. “Patients will soon be able to ...
... welcomed the Government’s decision to officially recognise the Australian ... for rural GPs. ,“Rural GPs are the ... ,“Formal recognition for rural GPs who complete ... workforce in rural and regional areas.” ,The ...
Cached Medicine News:Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 2Health News:Doctors Treat Early Heart Attacks Before Labs Could Confirmation It 3Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 3Health News:Campaign Against Obesity Taken to Schools in US 2Health News:Parents To Blame For Soaring Counts Of Binge-Drinkers And Smokers 2Health News:NHS Online- Promise Of ‘Choices’ To Patien 2